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Fatigue, anxiety, depression and sleep
quality in patients undergoing
haemodialysis
Zakariya Al Naamani1*, Kevin Gormley2, Helen Noble1, Olinda Santin1 and Mohammed Al Maqbali3
Abstract
Objective: Patients undergoing haemodialysis may experience troubling symptoms such as fatigue, anxiety,
depression and sleep quality, which may affect their quality of life. The main objective of this study is to determine
the prevalence of fatigue, anxiety, depression and sleep quality among patients receiving haemodialysis during the
coronavirus disease 2019 (COVID-19) pandemic, and to explore the contributing predictors.
Methods: A cross-sectional and descriptive correlational design using Qualtrics software was performed. Data were
collected using the Functional Assessment of Cancer Therapy-Fatigue (FACT-F), the Hospital Anxiety and Depression
Scale (HADS) and the Pittsburgh Sleep Quality Index (PSQI). Logistic regression analyses were used to explore the
predictors that were associated with fatigue, anxiety, depression and sleep quality.
Results: Of the 123 patients undergoing haemodialysis who participated, 53.7% (n = 66) reported fatigue, 43.9%
(n = 54) reported anxiety, 33.3% (n = 41) reported depression and 56.9% (n = 70) reported poor sleep. Fatigue,
anxiety and sleep quality (P < .05) were significantly associated with being female, and whether family members or
relatives were suspected or confirmed with COVID-19. Logistic regression showed that being within the age group
31–40, having a secondary education level, anxiety, depression and sleep quality were the main predictors affecting
the fatigue group.
Conclusion: Fatigue, anxiety, depression and sleep quality are significant problems for patients receiving
haemodialysis during the COVID-19 pandemic. Appropriate interventions to monitor and reduce fatigue,
psychological problems and sleep quality amongst these patients are needed. This can help to strengthen
preparations for responding to possible future outbreaks or pandemics of infectious diseases for patients receiving
haemodialysis.
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Introduction
In 2020, the coronavirus disease 2019 (COVID-19) is
considered a major challenge to healthcare systems
worldwide. COVID-19 is a highly contagious virus that
causes severe acute respiratory distress in humans. On
March 2020, the World Health Organization (WHO) de-
clared COVID-19 a global pandemic due to the rapid
outbreak of the virus [1]. COVID-19 caused a significant
and serious threat to people, especially those with under-
lying comorbidities such as patients with end-stage kid-
ney disease (ESKD).
Patients with ESKD receiving in-centre haemodialysis
are highly susceptible to COVID-19 infection because
the haemodialysis environment is a high risk area during
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the virus outbreak and patients’ immunity is compro-
mised due to the disease process [2]. These patients nor-
mally receive regular haemodialysis treatment, three
times a week, in overcrowded and congested halls,
mixed with various age groups from different back-
grounds, making it difficult to adhere to all COVID-19
protection guidelines, especially the application of isola-
tion and social distancing. Several studies have reported
that haemodialysis patients have a significantly increased
risk of transmission of infection with COVID-19 and a
higher mortality rate compared with the general popula-
tion [3, 4]. In a single center in Italy where 55 haemodi-
alysis patients were infected with COVID-19, thirteen
patients (52%) died [5].
Patients receiving haemodialysis experience debilitat-
ing psychological symptoms from the exhausting chronic
haemodialysis treatment that negatively impacts on their
mental health [6, 7]. The high prevalence and worrying
consequences of COVID-19 might induce psychological
distress among haemodialysis patients. Further under-
standing of the psychological disturbances that haemodi-
alysis patients might experience during the COVID-19
pandemic is essential to promote good mental health.
Therefore, this study is to determine the prevalence of
fatigue, anxiety, depression and sleep quality among pa-
tients receiving haemodialysis during the coronavirus




The study employed a large-scale cross-sectional, de-
scriptive, correlational design. The survey was developed
using an online platform (Qualtrics). Convenience sam-
pling technique was used to collect responses. Partici-
pants were invited, through a link, to complete the
questionnaire, which was sent by social media. Upon
opening the link, participants were prompted to read the
study’s introduction and decide whether they wanted to
participate. Those who agreed to take part provided con-
sent by clicking an “I consent to participate” box, pre-
sented prior to the start of the survey. This study
adhered to the Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE) guideline for
cross-sectional studies [8].
Setting and sampling
The participants were recruited from across all Ministry
of Health institutions in Oman. The study was per-
formed from 1st September 2020 to 20th September
2020. The inclusion criteria for participating in the study
were as follows: adult patient older than 18 years; diag-
nosed with ESKD and receiving haemodialysis for at
least three months; no known psychiatric or neurological
disorders that could interfere with study participation.
Exclusion criteria included patients who were diagnosed
with cancer or dementia.
Measures
The questionnaires included detailed demographics,
background history and scales, including the Functional
Assessment of Cancer Therapy-Fatigue (FACT-F), the
Pittsburgh Sleep Quality Index (PSQI), and the Hospital
Anxiety and Depression Scale (HADS).
Demographics
Information about participants’ age, sex, marital status,
education and occupational status were obtained in the
survey. In addition, participants were asked whether or
not their relatives had either suspected or confirmed
COVID-19?
Fatigue
Fatigue was measured using the FACT-F This instru-
ment consists of 13-items that assess self-reported fa-
tigue over the past seven days [9]. Response options are
on a 5-point Likert scale and range from 0 to 4. Total
possible scores of the FACT-F range from 0 to 52. A
higher score indicates less or no fatigue, whereas a lower
score indicates more fatigue. Alexander et al. detected a
cut-off point of equal or less than 36 indicating clinically
significant fatigue [10]. The original FACT-F showed
strong internal consistency (coefficient alpha 0.93–0.95)
and good stability (test-retest r = 0.87) [9, 11].
Depression and anxiety
The HADS includes 14 items assessing anxiety (7-items)
and depression (7-items), which are rated on a 4-point
Likert-type response (from 0 to 3) [12]. The scores in
each subscale are computed by summing the corre-
sponding items, with maximum scores of 21 for each
subscale. The recommended cut-off values are ≥8 either
for anxiety or depression [13]. The HADS showed very
good internal consistency (Cronbach’s α = .83) [14].
Sleep quality
The PSQI self-rated questionnaire assesses sleep quality
over the past month [15]. The PSQI has 19-items that
are categorised into seven components: subjective sleep
quality, sleep latency, sleep duration, habitual sleep effi-
ciency, sleep disturbances, use of sleep medications and
daytime dysfunction. The score for each of the seven
components can range from 0 to 3. The PSQI global
score is calculated by the sum of the seven components,
which ranges from 0 to 21, with a global score ≥ 5 indi-
cating poor sleep quality in the previous month. The
PSQI has acceptable reliability in Arabic (Cronbach’s
α = .77) [16].
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Data analysis
The data was entered into the Statistical Package for So-
cial Sciences (SPSS) version 25. In order to address the re-
search questions, descriptive statistics were calculated in
the form of means, standard deviations, standard errors,
frequencies, percentages of all the scales and subscales
and participant variables. Chi-squares (or Fisher’s exact
test) were used to test whether the levels of fatigue, anx-
iety, depression and sleep quality differ in terms of demog-
raphy and treatment. The correlation between fatigue,
anxiety, depression and sleep quality was analysed used
Pearson or Spearman’s rank correlation as appropriate.
Logistic regression analyses were used to identify the pre-
dictive risk factors for fatigue, anxiety, depression and
sleep quality, and the independent variable (age, sex, mari-
tal status, education, occupation and relatives having sus-
pected or confirmed COVID-19. P > .05 was considered to
be statistically significant for all analyses.
Ethical considerations
Ethical permission was sought from the Research and
Ethical Review and Approval Committee in the
Directorate General of Planning and Studies at the Min-
istry of Health in Oman (MoH/CSR/18/9002). The con-
fidentiality and privacy of the participants were
maintained. The consent statement was obtained, as it is
presented on the first screen of the survey tool. The
study was performed according to the principles of the
Declaration of Helsinki.
Results
A total of 123 valid questionnaires were received
through the online survey (Seen Fig. 1 for study flow
diagram). The majority of the participants were male
(67.3%, n = 83), and were married (82.1%, n = 101). The
largest age group was those aged 31 to 40 years (43.1%,
n = 53), followed by 41 to 50 years (30.1%, n = 37).
Around half of the participants had confirmed or sus-
pected COVID-19 among relatives (47.2%, n = 58). Over-
all, the prevalence of fatigue was 53.7%(n = 66), anxiety
was 43.9% (n = 54), depression was 33.3% (n = 41), and
poor sleep was 56.9% (n = 70). There were no differences
in reporting fatigue, anxiety, depression and sleep quality
Fig. 1 Flow diagram to show recruitment of participants
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according to age, marital status, educational level and
occupation (P>0.05).
As shown in Table 1, there were significant differences
in reports of fatigue according to gender (p < 0.05), with
the highest proportion of fatigue among female partici-
pants (42.4% vs 21.1%) compared with the non-fatigue
groups. There were significant differences in the report-
ing of fatigue (p < 0.05) according to those with relatives
with suspected or confirmed COVID-19 (59.1% vs.
33.3%); they were more likely to have fatigue compared
to the non-fatigue groups. Fatigue groups were more
likely than non-fatigue groups to have anxiety (85.2% vs.
29%, p < .001), depression (80.5% vs. 40.2%, p < .001) and
poor sleep quality (74.3% vs. 26.4%, p < .001).
Comparisons showed that depression groups were sta-
tistically significantly higher in female participants
(43.1% vs. 26.8%) (p < 0.05). Depressed respondents were
significantly more likely that non depressed respondents
to have fatigue (50% vs. 14%, p < .001), anxiety (51.9% vs.
18.8%, p < .001) and poor sleep quality (44.3% vs. 18.9%,
p < .001).
There were significant differences in reports of anxiety
according to gender (female:46.3% vs. 21.7%) and those
with relatives with suspected or confirmed COVID-19
(68.5% vs. 30.4%) (p < 0.05) compared with the non-
anxiety groups. There were significant differences in the
reporting of anxiety according to fatigue (86% vs. 14%,
p < .001), depression (68.3% vs. 31.7%, p < .001), and poor
sleep quality (62.9% vs. 18.9%, p < .001); all of whom
were more likely to have anxiety compared to the non-
anxiety groups.
The poor sleeper groups had significantly more female
participants (41.4% vs. 20.8%) as did those with relatives
with suspected or confirmed COVID-19 (61.4% vs.
28.3%) (p < 0.05) compared to the good sleeper groups.
Poor sleep was more prevalent among participants with
fatigue (78.8% vs. 31.6%, p < .001), anxiety (81.5% vs.
37.7%, p < .001) and depression (75.6% vs. 47.6%,
p < .001), when compared with the good sleeper group.
Predictive factors associated with fatigue, anxiety,
depression and sleep quality
Four logistic regressions were conducted to identify pre-
dictors of fatigue, anxiety, depression and sleep quality
(Table 2).
Five independent variables were significantly associ-
ated with fatigue (Table 2). The strongest predictor of
fatigue was patients with depression were 7.9 times more
likely to suffer fatigue (95% CI:2.32–27.51; p >.001). The
second predicate of fatigue was anxiety; patients with
anxiety were 6.3 times more likely to suffer fatigue (95%
CI: 1.76–22.88; p >.001). Participants with poor sleep
were 3.8 times (95% CI: 1.26–11.85; p >.001) more likely
to experience fatigue. The 31–40 age group and
secondary education level also significantly predicted fa-
tigue (p < 0.05).
The logistic regression model of anxiety showed that
patients with fatigue were 7.9 times more likely to have
anxiety (95% CI: 2.18–24.93; p >.001). Patients with a
family member with suspected or confirmed COVID-19
were 4.1 times more likely to have anxiety (95% CI:
1.47–11.66; p >.05). Poor sleep was significantly a predi-
cator of anxiety (OR: .30; 95% CI: 0.09–0.95; p >.05).
In the depression logistic regression model, fatigue
was the strongest predictor with participants being 4.9
time more likely to suffer depression (95% CI: 1.48–
16.38; p >.05). The secondary education level also signifi-
cantly predicted depression (OR: .29; 95% CI: 0.08–1.01;
p = .05).
The unemployed patients had the strongest predicator
and were 13.3 times more likely to report poor sleep
(95% CI: 0.09–0.95; p >.05). Being married appeared to
be the second predicate of poor sleep (OR 5.41; 95% CI:
1.12–26.28; p = .04). The models showed that patients
having fatigue and anxiety were significant predictors of
poor sleep.
Discussion
To our knowledge, this is the first study to examine the
prevalence of fatigue, anxiety, depression and sleep qual-
ity among patients undergoing haemodialysis in a middle
eastern country during the COVID-19 pandemic. In this
study, the prevalence of fatigue, anxiety, depression and
sleep quality resulting from the pandemic among pa-
tients having haemodialysis is 53.7, 43.9, 33.3 and 56.9%,
respectively. These results are higher than those found
in previous research in patients receiving haemodialysis.
Including fatigue (47%) [17], anxiety (17.5%) [18], de-
pression (28%) [19] and sleep quality (48%) [20].
Compared to results of previous studies in general
populations during the COVID-19 pandemic, the preva-
lence of anxiety, depression and sleep quality in this
study was higher [21–23], which may be related to the
high risk of dying of COVID-19 among patients with co-
morbidities and ESKD [24, 25]. This difference may be
partially explained by the different isolation measures
that were applied by countries to reduce the spread of
COVID-19, which can affect patients receiving haemodi-
alysis. In addition, the varied cultural norms, beliefs and
values between countries may affect the status of fatigue,
anxiety, depression and sleep quality. Another possible
reason for the differences in prevalence the diversity of
the assessment scale and healthcare system between the
studies.
The present study indicates that female patients having
haemodialysis had the highest levels of fatigue, anxiety,
depression and sleep quality. These findings are consist-
ent with general female populations during the COVID-
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19 pandemic [26–28]. Likewise, in this study, female pa-
tients were significantly associated with anxiety. Which
may have been be due to worry about their family
during the COVID-19 outbreak, and the consequences
for their family if they were to become infected. Further,
several studies have suggested that female gender is






























n % n % n % p n % n % p n % n % p n % n % p
Gender .01 .00 .04 .01
Male 83 67.5 38 57.6 45 78.9 29 53.7 54 78.3 23 56.1 60 73.2 41 58.6 42 79.2
Female 40 32.5 28 42.4 12 21.1 25 46.3 15 21.7 18 43.9 22 26.8 29 41.4 11 20.8
Age .06 .44 .89 .50
18–30 21 17.1 9 13.6 12 21.1 8 14.8 13 18.8 6 14.6 15 18.3 10 14.3 11 20.8
31–40 53 43.1 34 51.5 19 33.3 26 48.1 27 39.1 17 41.5 36 43.9 34 48.6 19 35.8
41–50 37 30.1 20 30.3 17 29.8 17 31.5 20 29 14 34.1 23 28 19 27.1 18 34
More than 50 12 9.8 3 4.5 9 15.8 3 5.6 9 13 4 9.8 8 9.8 7 10 5 9.4
Marital Status .39 .52 .50 .16
Married 101 82.1 56 84.8 45 78.9 43 79.6 58 84.1 35 85.4 66 80.5 60 85.7 41 77.4
Single 22 17.9 10 15.2 12 21.1 11 20.4 11 15.9 6 14.6 16 19.5 10 14.3 12 22.6
Education Level .30 .90 .16 .93
Basic 8 6.5 5 7.6 3 5.3 4 7.4 4 5.8 4 9.8 4 4.9 5 7.1 3 5.7
Secondary 33 26.8 21 31.8 12 21.1 15 27.8 18 26.1 7 17.1 26 31.7 19 27.1 14 26.4
Degree 82 66.7 40 60.6 42 73.7 35 64.8 47 68.1 30 73.2 52 63.4 46 65.7 36 67.9
Occupational .08 .24 .91 .06
Employed 87 70.7 44 66.7 43 75.4 37 68.5 50 72.5 28 68.3 59 72 44 62.9 43 81.1
Unemployed 25 20.3 18 27.3 7 12.3 14 25.9 11 15.9 9 22 16 19.5 19 27.1 6 11.3




.00 .00 .52 .00
Yes 58 47.2 39 59.1 19 33.3 37 68.5 21 30.4 21 51.2 37 45.1 43 61.4 15 28.3
No 65 52.8 27 40.9 38 66.7 17 31.5 48 69.6 20 48.8 45 54.9 27 38.6 38 71.7
Fatigue .00 .00 .00
No-Fatigue (FACIT-F≥
36)
57 46.3 – – – – 8 14.8 49 71 8 19.5 49 59.8 18 25.7 39 73.6
Fatigue (FACIT-F < 36) 66 53.7 – – – – 46 85.2 20 29 33 80.5 33 40.2 52 74.3 14 26.4
HADS Anxiety .00 .00 .00
No Anxiety
(HADS(A) < 8)
54 43.9 20 30.3 46 69.7 – – – – 13 31.7 56 68.3 26 37.1 43 81.1
Anxiety (HADS(A) ≥ 8) 69 65.1 49 86 8 14 – – – – 28 68.3 26 31.7 44 62.9 10 18.9
HADS Depression .00 .00 .00
No Depression
(HADS(D) < 8)
41 33.3 33 50 49 86 26 48.1 56 81.2 – – – – 39 55.7 43 81.1
Depression
(HADS(D)≥ 8)
82 66.7 33 50 8 14 28 51.9 23 18.8 – – – – 31 44.3 10 18.9
PSQI .00 .00 .00
Good Sleeper 53 43.1 14 21.2 39 68.4 10 18.5 43 62.3 10 24.4 43 52.4 – – – –
Poor Sleep 70 56.9 52 78.8 18 31.6 44 81.5 26 37.7 31 75.6 39 47.6 – – – –
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associated with increased prevalence of fatigue, anxiety,
depression and sleep quality among patients receiving
haemodialysis [29–31].
The results of this study show that participants
have significantly increased risk of fatigue, anxiety
and sleep quality if their family members are diag-
nosed with or have suspected COVID-19. This may
be due to patients receiving haemodialysis being
afraid of infection, either from the hospital setting or
their families. It has been reported that haemodialysis
patients who develop COVID-19 have high mortality
rates [31, 32].
In this study, being unemployed appears to be the
highest predicator of poor sleep. Previous research has
reported similar findings [33, 34]. One explanation of
this result is that unemployed patients do not have a
regular routine in their daily lives. in the present study,
depression was significantly associated with poor sleep.
Likewise, several studies have found that depression has
a significant effect on poor sleep quality in patients re-
ceiving haemodialysis [35, 36].
The study has a number of limitations. First, this study
was conducted in Oman, which may limit generalization
to other countries. Second the study utilised a cross-
sectional design; therefore, it represents the evaluation
of fatigue, anxiety, depression and poor sleep quality at
one point in time, without longitudinal observation of
participants. Finally, the study relied on the participants’
self-reporting questionnaires to assess psychological
problems; however, this may differ from a clinical diag-
nostic interview. Further, objective measurement of sleep
was not performed in the current study; however, the
PSQI questionnaire showed good validity and reliability
to measure sleep quality.
Altogether, fatigue, anxiety, depression and sleep qual-
ity are significant problems for patients undergoing
haemodialysis. The results of the current study have a
number of potential implications for interventions to
Table 2 Logistic regression analyses of factors associated with Fatigue, Depression, Anxiety, Sleep Disturbance Odds Ratio (95% CI)
Fatigue Depression Anxiety Poor Sleep
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Gender
Female Ref
Male 0.77 (0.22–2.76) 0.69 0.50 (0.16–1.53) 0.22 0.44 (0.13–1.56) 0.21 0.81 (0.24–2.68) 0.73
Age
More than 50 Ref
18–30 0.25 (0.01–4.5) 0.34 0.60 (0.05–6.78) 0.67 0.79 (0.06–10.62) 0.86 0.43 (0.05–4.00) 0.46
31–40 0.08 (0.01–1.07) 0.05 0.40 (0.05–3.43) 0.40 0.58 (0.06–5.56) 0.63 0.78 (0.12–5.16) 0.79
41–50 0.12 (0.01–1.49) 0.1 0.60 (0.08–4.40) 0.61 1.37 (0.16–12.12) 0.78 0.22 (0.04–1.34) 0.10
Marital Status
Single Ref
Married 0.34 (0.06–1.78) 0.2 1.19 (0.30–4.77) 0.80 0.28 (0.06–1.25) 0.10 5.41 (1.12–26.28) 0.04
Education Level
Degree Ref
Basic 0.38 (0.018–8.12) 0.53 0.72 (0.08–6.40) 0.77 2.01 (0.15–27.13) 0.60 0.11 (0.01–1.45) 0.09
Secondary 0.26 (0.07–0.99) 0.04 0.29 (0.08–1.01) 0.05 1.68 (0.47–5.95) 0.43 0.43 (0.12–1.53) 0.19
Occupational
Employed Ref
Unemployed 0.23 (0.03–1.84) 0.16 0.66 (0.13–3.43) 0.61 0.39 (0.07–2.22) 0.29 13.36 (1.73–102.97) 0.01
Retired 1.24 (0.14–11.28) 0.84 1.83 (0.27–12.24) 0.53 0.35 (0.04–2.99) 0.34 3.95 (0.71–22.10) 0.12
Families or Relatives Suspected or Confirmed
No Ref
Yes 0.67 (0.21–2.11) 0.49 0.43 (0.15–1.26) 0.12 4.15 (1.47–11.66) 0.01 2.52 (0.92–6.91) 0.07
Fatigue – 4.93 (1.48–16.38) 0.01 7.37 (2.18–24.93) 0.00 3.53 (1.12–11.11) 0.03
Depression 7.98 (2.32–27.51) 0.00 – 0.38 (0.12–1.24) 0.11 0.57 (0.18–1.77) 0.33
Anxiety 6.35 (1.76–22.88) 0.00 0.37 (0.12–1.20) 0.1 – 0.27 (0.08–0.89) 0.03
Poor Sleep 3.86 (1.26–11.85) 0.01 0.57 (0.18–1.80) 0.34 0.30 (0.09–0.95) 0.04 –
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improve psychological wellbeing of these patients. For
example, organizations should provide counselling sup-
port services or online workshops and training material
to enable patients to identify and overcome psycho-
logical problems. In addition, nurses play an essential
role in helping to improve fatigue, anxiety, depression
and sleep quality by providing high quality haemodialysis
and creating a favourable environment for holistic care
in renal dialysis units.
Further research should consider longitudinal design
to identify the prevalence of fatigue, anxiety, depression
and sleep quality before, during and after pandemic.
Additionally, qualitative interview approaches will help
to provide comprehensive in-depth understanding of fa-
tigue, anxiety, depression and sleep quality and inform
recommendations to improve further practice for those
symptoms. Further research is needed to investigate the
patients’ perceptions about the management strategy.
Conclusion
This study is the first to describe fatigue, anxiety, de-
pression and sleep quality among patients undergoing
haemodialysis during the period of the COVID-19 out-
break. It will be helpful for dialysis staff and healthcare
professionals as they identify risk predictors and the bur-
dens of fatigue, anxiety, depression and sleep quality,
and develop strategies to improve these symptoms
among patient undergoing haemodialysis. Furthermore,
it gives a solid foundation for further research, which
should identify appropriate interventions to reduce fa-
tigue, anxiety, depression and sleep quality of patients
undergoing haemodialysis.
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